Study Interplay between Adropin, Oxidative Stress, and Polycystic Ovarian Syndrome

This Study Interplay investigates evaluates and compares the relationship of Adropin with oxidative stress as a clinical predictor for the development of polycystic ovarian syndrome (PCOS). A clinical investigation was undertaken from January 2023 to the end of April 2023 for 63 women with PCOS diagnosed based on Rotterdam criteria, from the Al-Batoul Teaching Hospital (Obstetrics and Gynecology) in Mosul City/Iraq, as well as, 47 women with regular menstrual cycles as a non-PCOS group. Significant increases (P ≤ 0.05) were in the Body mass index (BMI), Waist-to-height ratio (WHtR), systolic blood pressure (SBP), and diastolic blood pressure (DBP), in addition to total cholesterol (TC), triglycerides(TG), non-high-density lipoprotein(non-HDL), glucose, insulin, insulin resistance (HOMA-IR), peroxynitrite, malondialdehyde and the activity of peroxidase, but a significant decrease in HDL, vitamin C, vitamin E, glutathione, and the activity of the arylesterase in PCOS as compared to a non-PCOS group. Adropin levels were a significant decrease with getting older in all participants. Also, in PCOS patients compared to non-PCOS (P≤0.05). A negative correlation (p≤0.05) between Adropin levels and BMI, blood pressure, TC, TG, non-HDL, glucose, insulin, (HOMA-IR), and Malondialdehyde. In addition, a positive correlation with HDL in PCOS, which appears to be an Adropin level, may have a significant role in initiating and developing PCOS.